AUTHORS
Sam Hirniak, PhD, Andrea Edginton, PhD2, Alfonso Iorio, MD, PhD3, William WL Wong4, George Goshua, MD, SM5
AFFILIATIONS
1 Yale Cancer Center, New Haven, Connecticut, United States, Yale School of Medicine, New Haven, Connecticut, United States
2 University of Waterloo, Kitchener, Ontario, Canada
3 McMaster University, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
4 University of Waterloo, Kitchener, Ontario, Canada
5 Yale Cancer Center, New Haven, Connecticut, United States, Yale School of Medicine, New Haven, Connecticut, United States
ABSTRACT
Introduction: Both gene therapy (GT) and emicizumab prophylaxis have repeatedly demonstrated a reduction in the need for factor prophylaxis self-infusions for people living with hemophilia A, moving the care of these patients closer toward an aspirational patient-centric goal of the hemophilia-free mind. For some people living with hemophilia A, GT durability is time-limited with waning factor VIII levels. So, the ability to proceed with subsequent emicizumab prophylaxis, in case of gene therapy efficacy loss versus factor-based prophylaxis, would provide improved health-related quality of life. This study sought to evaluate the cost-effectiveness of GT with subsequent emicizumab prophylaxis in case of GT efficacy loss versus established prophylaxis options without GT needed to inform the Canadian health technology decision making process.
Methods: We built a whole body hemophilia joint health score (HJHS)-anchored microsimulation of adult men living with severe hemophilia A without inhibitors sourced from the Canadian Bleeding Disorder Registry (CBDR; mean age of 38 and mean weight of 85kg) with known individualized HJHS scores from the KAPPA register. The interventions evaluated were 1) GT with emicizumab in the event of GT efficacy loss, 2) emicizumab alone, 3) standard half-life (SHL), 4) extended half-life (EHL), and 5) efanesoctocog alfa (EA). Effectiveness was measured in quality-adjusted life years (QALYs) and parameterized using baseline age-specific utilities, accounting for disutilities with HJHS score progression, infusions, bleeds, and adverse events. Costs were assessed using 2025 Canadian dollars (CAD), with healthcare costs informed by administrative data and individual joint damage level as defined by the HJHS. The primary outcome was the incremental cost-effectiveness ratio (ICER), with purchasing power parity (PPP)-adjusted United States’ GT price (CAD $3.49 million), reported over a lifetime time-horizon at an accepted Canadian willingness-to-pay threshold of $50,000/QALY. Secondary outcomes were the number of lifetime bleeds, the average time with an HJHS less than 15, and the price threshold where gene therapy becomes cost-effective. Given anticipated therapeutic advancements in non-AAV vector gene therapy, we additionally evaluated two redosable gene therapy scenarios, as follows: 1) redosable (non-AAV vector) GT with both same price and durability as current non-redosable (AAV vector) GT; and 2) redosable (non-AAV vector) GT with one year durability at a reduced price point of $1 million. We concluded with sensitivity analyses to evaluate the effect of second-order uncertainty propagation simultaneously across all parameters.
Results: GT with emicizumab use in case of efficacy loss, emicizumab alone, SHL, EHL and EA accrued 28.5, 27.8, 24.3, 27.1, and 28.7 lifetime QALYs. The estimated Canadian lifetime costs were $33.8 million (M), 33.5M, 35.4M, 35.0M, and 67.8M, respectively. The ICER for GT (with emicizumab in case of efficacy loss) versus emicizumab alone was CAD $483,000/QALY. The mean respective lifetime bleeds with each strategy were 55, 61, 171, 60, 30. The mean respective projected time with a whole body HJHS of less than 15 was 14.7, 12.7, 12.7, 12.6, 13.5 years. Price threshold analysis demonstrated that GT would become cost-effective with a 6% price reduction to CAD $3.2M. Prophylaxis with emicizumab alone was the cost-effective strategy across 94% of all second-order Monte Carlo draws in probabilistic sensitivity analysis. The first redosable GT scenario increased cost to $35.5M with an improvement to 30.16 QALYs while decreasing average lifetime bleeds to 28. The second scenario of redosable GT—with a 1-year limited durability at a reduced price of $1M—increase cost further to $36.0M alongside increased lifetime bleeds to 46 with decrease in QALYs to 29.16.
Conclusion: Gene therapy with emicizumab prophylaxis in case of efficacy loss would be cost-effective within the Canadian market with a gene therapy price of $3.2M. Additionally, redosable non-AAV vector gene therapy has the potential to become cost-effective in the Canadian market, dependent on redosable GT price and durability. These results fill a crucial gap for the Canadian health technology decision making process.
DISCLOSURES
Sam Hirniak, PhD: No relevant conflicts of interest to declare.